HanchorBio scores first FDA orphan drug tag for gastric cancer therapy

The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients

Dewpoint Therapeutics selects groundbreaking MYC development candidate

MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control

Centivax launches first human trial of universal flu vaccine

BioAsia 2026 positions Telangana as a global TechBio powerhouse

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%

The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion

The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway

Cirena launches to revolutionize long RNA production for CRISPR & gene editing

As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects